VXRT News and Press, Vaxart Inc. From 09/01/22

Vaxart ( NASDAQ: VXRT ) said its Wuhan S-only oral pill COVID-19 vaccine VXA-CoV2-1.1-S. met the main safety and secondary immunogenicity goals in the first part of a planned two-part phase 2 trial. Part 1 of the study enrolled 66 healthy adults, including people wh...

— Study met primary safety and secondary immunogenicity endpoints — — Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects — — Elicited cross-reactive mucosal responses in appro...

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022. T...

Ray Stapleton has been appointed as Chief Technology Officer (CTO) at Vaxart ( NASDAQ: VXRT ), effective immediately. Prior to this appointment, Dr. Stapleton served as CTO and Executive Vice President at Genocea, working to develop next-generation personalized immunothera...

Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) announced ...

Vaxart, Inc. (VXRT) Q2 2022 Earnings Conference Call August 08, 2022, 16:30 ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chief Me...

Vaxart press release ( NASDAQ: VXRT ): Q2 GAAP EPS of -$0.23. Revenue of $0M. Shares -6.8% . Ended second quarter with $131.5 million in cash, cash equivalents and marketable securities The Company reported a net loss of $29.4 million for...

Top-line data from COVID-19 Phase II study expected in the third quarter of 2022 Vaxart initiates work on vaccine candidates that directly target new omicron variants of concern Positive data from norovirus trial in elderly show similar immunogenicity to younger adul...

Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that W. Mark Watson was appointed to the Company’s Board of Directors, effe...

Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...